Tutorials
Nkarta Inc logo

Nkarta Inc

$ 15.86 -0.33 (-2.04%) 10:07 AM EST
P/E:
At Loss
P/B:
2.31
Market Cap:
$ 774.95M
Enterprise V:
$ 635.95M
Volume:
70.12K
Avg Vol (2M):
609.72K
Volume:
70.12K
Market Cap $:
774.95M
PE Ratio:
At Loss
Avg Vol (2-Month):
609.72K
Enterprise Value $:
635.95M
PB Ratio:
2.31
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Nkarta Inc
NAICS : 541714 SIC : 2834
6000 Shoreline Court, Suite 102, South San Francisco, CA, USA, 94080
Description
Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment.
Name Current Vs Industry Vs History
Cash-To-Debt 3.13
Equity-to-Asset 0.75
Debt-to-Equity 0.3
Debt-to-EBITDA -0.76
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 84.79
9-Day RSI 74.18
14-Day RSI 67.41
6-1 Month Momentum % 47.2
12-1 Month Momentum % -62.37

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 20.59
Quick Ratio 20.59
Cash Ratio 20.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -87.2

Profitability Rank

Name Current Vs Industry Vs History
ROE % -34.48
ROA % -30.74
ROIC % -213.74
ROC (Joel Greenblatt) % -267.3
ROCE % -32.04

Financials (Next Earnings Date:2022-08-12 Est.)

NKTX's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:NKTX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -2.82
Beta 0
Volatility % 96.8
14-Day RSI 67.41
14-Day ATR ($) 1.043082
20-Day SMA ($) 13.758
12-1 Month Momentum % -62.37
52-Week Range ($) 7.55 - 40.64
Shares Outstanding (Mil) 48.4

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Nkarta Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More